These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31297736)

  • 1. Latent tuberculosis treatment completion rates from prescription drug administrative data.
    Plourde PJ; Basham CA; Derksen S; Schultz J; McCulloch S; Larcombe L; Kinew KA; Lix LM
    Can J Public Health; 2019 Dec; 110(6):705-713. PubMed ID: 31297736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
    Arguello Perez E; Seo SK; Schneider WJ; Eisenstein C; Brown AE
    Clin Infect Dis; 2017 Nov; 65(12):2105-2111. PubMed ID: 29020308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
    Schein YL; Madebo T; Andersen HE; Arnesen TM; Dyrhol-Riise AM; Tveiten H; White RA; Winje BA
    BMC Infect Dis; 2018 Nov; 18(1):587. PubMed ID: 30453946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Quach P; Skidmore B; Moher D; Alvarez GG
    BMC Infect Dis; 2017 Apr; 17(1):265. PubMed ID: 28399802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
    McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
    BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.
    Schmit KM; Lobato MN; Lang SG; Wheeler S; Kendig NE; Bur S
    J Public Health Manag Pract; 2019; 25(2):E1-E6. PubMed ID: 30024493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Rifapentine and Isoniazid Directly Observed Therapy for the Treatment of Latent Tuberculosis Infection in a Military Clinic.
    Jinbo J; Lustik M; West GF; Kloetzel M
    Mil Med; 2017 Sep; 182(9):e2024-e2029. PubMed ID: 28885972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study.
    Rubinowicz A; Bartlett G; MacGibbon B; Greenaway C; Ronald L; Munoz M; Menzies D
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1449-54. PubMed ID: 25517810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
    Fresard I; Bridevaux PO; Rochat T; Janssens JP
    Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
    Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 12. Improving Treatment Completion Rates for Latent Tuberculosis Infection: A Review of Two Treatment Regimens at a Community Health Center.
    Lines G; Hunter P; Bleything S
    J Health Care Poor Underserved; 2015 Nov; 26(4):1428-39. PubMed ID: 26548690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.
    Johnston JC; van der Kop ML; Smillie K; Ogilvie G; Marra F; Sadatsafavi M; Romanowski K; Budd MA; Hajek J; Cook V; Lester RT
    Eur Respir J; 2018 Feb; 51(2):. PubMed ID: 29437940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic.
    Gaensbauer J; Aiona K; Haas M; Reves R; Young J; Belknap R
    Pediatr Infect Dis J; 2018 Mar; 37(3):224-228. PubMed ID: 28777204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated With Latent Tuberculosis Infection Treatment Failure Among Patients With Commercial Health Insurance-United States, 2005-2016.
    Iqbal SA; Isenhour CJ; Mazurek G; Langer AJ; Chang MH; Truman BI
    J Public Health Manag Pract; 2021 Jul-Aug 01; 27(4):E151-E161. PubMed ID: 31688742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to First-Line Antituberculosis Drugs in Washington State by Region of Birth and Implications for Latent Tuberculosis Treatment Among Foreign-Born Individuals.
    Furukawa NW; Haider MZ; Allen SJ; Carlson SL; Lindquist SW
    Am J Trop Med Hyg; 2017 Mar; 96(3):543-549. PubMed ID: 27994106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
    Lam CK; McGinnis Pilote K; Haque A; Burzynski J; Chuck C; Macaraig M
    J Med Internet Res; 2018 Nov; 20(11):e287. PubMed ID: 30459146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved treatment completion with shorter treatment regimens for latent tuberculous infection.
    Macaraig MM; Jalees M; Lam C; Burzynski J
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1344-1349. PubMed ID: 30355415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Completion rates of treatment for latent tuberculosis infection in Quebec, Canada from 2006 to 2010.
    Rivest P; Street MC; Allard R
    Can J Public Health; 2013 May; 104(3):e235-9. PubMed ID: 23823888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
    Haas MK; Aiona K; Erlandson KM; Belknap RW
    Clin Infect Dis; 2021 Nov; 73(9):e3459-e3467. PubMed ID: 32915203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.